A Randomized Double-Blind Placebo-Controlled Phase 3 Study of

Recruiting

99 years or below

All

1 Location

Brief description of study

This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B (80 mg) and each cohort further randomized 2:1 to receive ISIS 678354 or placebo in a 53-week Treatment Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Jun 2023. Study ID: 850921

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Randomized Double-Blind Placebo-Controlled Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Brief description of study

Eligibility of study

Find a site

Interested in the study